Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions

Journal of Investigative Dermatology

Volumn 135, Issue 9, 2015, Pages 2237-2248

  Chung, Wen Hung ^a,b   Pan, Ren You ^c   Chu, Mu Tzu ^d   Chin, See Wen ^a,b   Huang, Yu Lin ^a,b   Wang, Wei Chi ^e   Chang, Jen Yun ^e   Hung, Shuen Iu ^c,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c ACADEMIA SINICA   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e Health GeneTech Corporation   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; GAMMA INTERFERON; GRANULYSIN; OXIPURINOL; T LYMPHOCYTE RECEPTOR; GNLY PROTEIN, HUMAN; T LYMPHOCYTE ANTIGEN; THIAZOLE DERIVATIVE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRESS SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; GOUT; HUMAN; HUMAN CELL; HYPERURICEMIA; NATURAL KILLER CELL; NEXT GENERATION SEQUENCING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEVERE CUTANEOUS ADVERSE REACTION; SKIN DISEASE; SKIN NECROSIS; SKIN PRURITUS; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROSIS; ADULT; AGED; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; CROSS REACTION; DRUG EFFECTS; DRUG ERUPTIONS; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; REFERENCE VALUE; STEVENS-JOHNSON SYNDROME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CASE-CONTROL STUDIES; CELLS, CULTURED; CROSS REACTIONS; DRUG ERUPTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; OXYPURINOL; REFERENCE VALUES; STEVENS-JOHNSON SYNDROME; THIAZOLES;

EID: 84939463738     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.165     Document Type: Article

References (47)

1. Adam J, Eriksson KK, Schnyder B et al. (2012) Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol 42:1706-16
2. Auquier-Dunant A, Mockenhaupt M, Naldi L et al. (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138:1019-24
3. Barbaud A, Collet E, Milpied B et al. (2013) A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 168:555-62
4. Becker MA, Schumacher HR Jr., Wortmann RL et al. (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450-61
5. Betts MR, Brenchley JM, Price DA et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65-78
6. Bharadwaj M, Illing P, Theodossis A et al. (2012) Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 52:401-31
7. Braden GL, Warzynski MJ, Golightly M et al. (1994) Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 70: 145-51
8. Brunton LL, Chabner BA, Knollman BC (eds). (2011) Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th edn. Macmillan: New York
9. Chung WH, Hung SI, Hong HS et al. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486
10. Chung WH, Hung SI, Yang JY et al. (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14:1343-50
11. Chung WH, Chang WC, Lee YS et al. (2014a) Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312: 525-34
12. Chung WH, Chang WC, Stocker SL et al. (2014b) Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis advance online publication, 12 August 2014; pii: annrheumdis-2014-205577. doi:10.1136/annrheumdis-2014-205577 [e-pub ahead of print]
13. Espiritu CR, Alalu J, Glueckauf LG et al. (1976) Allopurinol-induced granulomatous hepatitis. Am J Dig Dis 21:804-6
14. Goldfarb DS, MacDonald PA, Hunt B et al. (2011) Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol 38:1385-9
15. Hetherington S, Hughes AR, Mosteller M et al. (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359: 1121-2
16. Hung SI, Chung WH, Liou LB et al. (2005) HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102:4134-9
17. Illing PT, Vivian JP, Dudek NL et al. (2012) Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486:554-8
18. Kang HR, Jee YK, Kim YS et al. (2011) Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 21:303-7
19. Kaniwa N, Saito Y, Aihara M et al. (2008) HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9:1617-22
20. Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al. (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156:609-11
21. Ko TM, Chung WH, Wei CY et al. (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 128:1266-76
22. Koning D, Costa AI, Hasrat R et al. (2014) In vitro expansion of antigen-specific CD8(+) T cells distorts the T-cell repertoire. J Immunol Methods 405: 199-203
23. Lin CH, Chen JK, Ko TM et al. (2015) Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B∗58:01-restricted activation of drug-specific T cells and molecular interaction. J Allergy Clin Immunol 135:1063-5
24. Lonjou C, Borot N, Sekula P et al. (2008) A European study of HLA-B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five highrisk drugs. Pharmacogenet Genomics 18:99-107
25. Macías E, Ruiz A, Moreno E et al. (2007) Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy 62:1462-4
26. Mallal S, Nolan D, Witt C et al. (2002) Association between presence of HLAB∗ 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 359:727-32
27. Naranjo CA, Busto U, Sellers EM et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-45
28. Ostrov DA, Grant BJ, Pompeu YA et al. (2012) Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 109:9959-64
29. Pan RY, Wu YC, Chung WH et al. (2014) HLA and TCR recognition of medications in severe cutaneous adverse reactions. Curr Immunol Rev 10:51-61
30. Phillips EJ, Mallal SA (2010) Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 11:973-87
31. PichlerWJ, Tilch J (2004) The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59:809-20
32. Posadas SJ, Padial A, Torres MJ et al. (2002) Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 109:155-61
33. Porebski G, Gschwend-Zawodniak A, Pichler WJ (2011) In vitro diagnosis of T cell-mediated drug allergy. Clin Exp Allergy 41:461-70
34. Porebski G, Pecaric-Petkovic T, Groux-Keller M et al. (2013) In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy 43:1027-37
35. Ramasamy SN, Korb-Wells CS, Kannangara DR et al. (2013) Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 36:953-80
36. Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. N Engl J Med 331:1272-85
37. Roujeau JC, Kelly JP, Naldi L et al. (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600-7
38. Roujeau JC (2006) Immune mechanisms in drug allergy. Allergol Int 55:27-33
39. Sassolas B, Haddad C, Mockenhaupt M et al. (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88:60-8
40. Sekula P, Dunant A, Mockenhaupt M et al. (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133:1197-204
41. Tassaneeyakul W, Jantararoungtong T, Chen P et al. (2009) Strong association between HLA-B∗5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19:704-9
42. Wang C, Sanders CM, Yang Q et al. (2010) High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. Proc Natl Acad Sci USA 107:1518-23
43. Wei CY, Chung WH, Huang HW et al. (2012) Direct interaction between HLAB and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 129:1562-9
44. Yousfi Monod M, Giudicelli V, Chaume D et al. (2004) IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 20:i379-85
45. Yun J, Adam J, Yerly D et al. (2012) Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy 67: 1338-46
46. Yun J, Mattsson J, Schnyder K et al. (2013) Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 43:1246-55
47. Yun J, Marcaida MJ, Eriksson KK et al. (2014) Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B∗58:01. J Immunol 192:2984-93